Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with
relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate
cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total
duration of approximately 30 weeks.